TRK-IN-33 is a TRK inhibitor that demonstrates exceptional ability to degrade TRKAG667C (DC50 = 24.69 nM, Dmax > 90%) while not affecting the wild-type protein. It exhibits antiproliferative activity against Ba/F3-LMNA-NTRK1G667C cells carrying NTRK1G667C, with an IC50 of 2.48 nM. TRK-IN-33 effectively inhibits tumor growth in vivo and induces apoptosis in tumor cells without significant toxicity. This compound is suitable for research in NTRK fusion-positive cancers.
Target:
Trk receptor|||Apoptosis
* VAT and and shipping costs not included. Errors and price changes excepted
